Cargando…

NI-12 The ratio of T1-Weighted to T2-Weighted Signal Intensity and IDH mutation in glioma

Introduction: Prediction of IDH mutation status for Lower-grade glioma (LrGG) is clinically significant. The purpose of this study is to test the hypothesis that the T1-weighted image/T2-weighted image ratio (rT1/T2), an imaging surrogate developed for myelin integrity, is a useful MRI biomarker for...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanada, Takahiro, Yamamoto, Shota, Sato, Hirotaka, Sakai, Mio, Saito, Masato, Mitsui, Nobuyuki, Hiroshima, Satoru, Anei, Ryogo, Kanemura, Yonehiro, Nakanishi, Katsuyuki, Kishima, Haruhiko, Kinoshita, Manabu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648184/
http://dx.doi.org/10.1093/noajnl/vdab159.074
_version_ 1784610751400378368
author Sanada, Takahiro
Yamamoto, Shota
Sato, Hirotaka
Sakai, Mio
Saito, Masato
Mitsui, Nobuyuki
Hiroshima, Satoru
Anei, Ryogo
Kanemura, Yonehiro
Nakanishi, Katsuyuki
Kishima, Haruhiko
Kinoshita, Manabu
author_facet Sanada, Takahiro
Yamamoto, Shota
Sato, Hirotaka
Sakai, Mio
Saito, Masato
Mitsui, Nobuyuki
Hiroshima, Satoru
Anei, Ryogo
Kanemura, Yonehiro
Nakanishi, Katsuyuki
Kishima, Haruhiko
Kinoshita, Manabu
author_sort Sanada, Takahiro
collection PubMed
description Introduction: Prediction of IDH mutation status for Lower-grade glioma (LrGG) is clinically significant. The purpose of this study is to test the hypothesis that the T1-weighted image/T2-weighted image ratio (rT1/T2), an imaging surrogate developed for myelin integrity, is a useful MRI biomarker for predicting the IDH mutation status of LrGG. Methods: Twenty-five LrGG patients (IDHwt: 8, IDHmt: 17) at Asahikawa Medical University Hospital (AMUH) were used as an exploratory cohort. Twenty-nine LrGG patients (IDHwt: 13, IDHmt: 16) from Osaka International Cancer Institute (OICI) and 103 patients from the Cancer Imaging Archive (TCIA) / Cancer Genome Atlas (TCGA) dataset (IDHwt: 19, IDHmt: 84) were used as validation cohorts. rT1/T2 images were calculated from T1- and T2-weighted images using a recommended signal correction. The region-of-interest was defined on T2-weighted images, and the relationship between the mean rT1/T2 (mrT1/T2) and the IDH mutation status was investigated. Results: The mrT1/T2 was able to significantly predict the IDH mutation status for the AMUH exploratory cohort (AUC = 0.75, p = 0.048). The ideal cut-off for detecting mutant IDH was mrT1/T2 < 0.666 ~ 0.677, with a sensitivity of 58.8% and a specificity of 87.5%. This result was further validated by the OICI validation cohort (AUC = 0.75, p = 0.023) with a sensitivity of 56.3% and a specificity of 69.2%. On the other hand, the sensitivity was 42.9% and the specificity was 68.4 % for the TCIA validation cohort (AUC = 0.63, p = 0.068). Conclusion: Our results supported the hypothesis that mrT1/T2 could be a useful image surrogate to predict the IDH mutation status of LrGG using two domestic cohorts. The decline of the accuracy for the TCIA cohort should be further investigated.
format Online
Article
Text
id pubmed-8648184
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86481842021-12-07 NI-12 The ratio of T1-Weighted to T2-Weighted Signal Intensity and IDH mutation in glioma Sanada, Takahiro Yamamoto, Shota Sato, Hirotaka Sakai, Mio Saito, Masato Mitsui, Nobuyuki Hiroshima, Satoru Anei, Ryogo Kanemura, Yonehiro Nakanishi, Katsuyuki Kishima, Haruhiko Kinoshita, Manabu Neurooncol Adv Supplement Abstracts Introduction: Prediction of IDH mutation status for Lower-grade glioma (LrGG) is clinically significant. The purpose of this study is to test the hypothesis that the T1-weighted image/T2-weighted image ratio (rT1/T2), an imaging surrogate developed for myelin integrity, is a useful MRI biomarker for predicting the IDH mutation status of LrGG. Methods: Twenty-five LrGG patients (IDHwt: 8, IDHmt: 17) at Asahikawa Medical University Hospital (AMUH) were used as an exploratory cohort. Twenty-nine LrGG patients (IDHwt: 13, IDHmt: 16) from Osaka International Cancer Institute (OICI) and 103 patients from the Cancer Imaging Archive (TCIA) / Cancer Genome Atlas (TCGA) dataset (IDHwt: 19, IDHmt: 84) were used as validation cohorts. rT1/T2 images were calculated from T1- and T2-weighted images using a recommended signal correction. The region-of-interest was defined on T2-weighted images, and the relationship between the mean rT1/T2 (mrT1/T2) and the IDH mutation status was investigated. Results: The mrT1/T2 was able to significantly predict the IDH mutation status for the AMUH exploratory cohort (AUC = 0.75, p = 0.048). The ideal cut-off for detecting mutant IDH was mrT1/T2 < 0.666 ~ 0.677, with a sensitivity of 58.8% and a specificity of 87.5%. This result was further validated by the OICI validation cohort (AUC = 0.75, p = 0.023) with a sensitivity of 56.3% and a specificity of 69.2%. On the other hand, the sensitivity was 42.9% and the specificity was 68.4 % for the TCIA validation cohort (AUC = 0.63, p = 0.068). Conclusion: Our results supported the hypothesis that mrT1/T2 could be a useful image surrogate to predict the IDH mutation status of LrGG using two domestic cohorts. The decline of the accuracy for the TCIA cohort should be further investigated. Oxford University Press 2021-12-06 /pmc/articles/PMC8648184/ http://dx.doi.org/10.1093/noajnl/vdab159.074 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Abstracts
Sanada, Takahiro
Yamamoto, Shota
Sato, Hirotaka
Sakai, Mio
Saito, Masato
Mitsui, Nobuyuki
Hiroshima, Satoru
Anei, Ryogo
Kanemura, Yonehiro
Nakanishi, Katsuyuki
Kishima, Haruhiko
Kinoshita, Manabu
NI-12 The ratio of T1-Weighted to T2-Weighted Signal Intensity and IDH mutation in glioma
title NI-12 The ratio of T1-Weighted to T2-Weighted Signal Intensity and IDH mutation in glioma
title_full NI-12 The ratio of T1-Weighted to T2-Weighted Signal Intensity and IDH mutation in glioma
title_fullStr NI-12 The ratio of T1-Weighted to T2-Weighted Signal Intensity and IDH mutation in glioma
title_full_unstemmed NI-12 The ratio of T1-Weighted to T2-Weighted Signal Intensity and IDH mutation in glioma
title_short NI-12 The ratio of T1-Weighted to T2-Weighted Signal Intensity and IDH mutation in glioma
title_sort ni-12 the ratio of t1-weighted to t2-weighted signal intensity and idh mutation in glioma
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648184/
http://dx.doi.org/10.1093/noajnl/vdab159.074
work_keys_str_mv AT sanadatakahiro ni12theratiooft1weightedtot2weightedsignalintensityandidhmutationinglioma
AT yamamotoshota ni12theratiooft1weightedtot2weightedsignalintensityandidhmutationinglioma
AT satohirotaka ni12theratiooft1weightedtot2weightedsignalintensityandidhmutationinglioma
AT sakaimio ni12theratiooft1weightedtot2weightedsignalintensityandidhmutationinglioma
AT saitomasato ni12theratiooft1weightedtot2weightedsignalintensityandidhmutationinglioma
AT mitsuinobuyuki ni12theratiooft1weightedtot2weightedsignalintensityandidhmutationinglioma
AT hiroshimasatoru ni12theratiooft1weightedtot2weightedsignalintensityandidhmutationinglioma
AT aneiryogo ni12theratiooft1weightedtot2weightedsignalintensityandidhmutationinglioma
AT kanemurayonehiro ni12theratiooft1weightedtot2weightedsignalintensityandidhmutationinglioma
AT nakanishikatsuyuki ni12theratiooft1weightedtot2weightedsignalintensityandidhmutationinglioma
AT kishimaharuhiko ni12theratiooft1weightedtot2weightedsignalintensityandidhmutationinglioma
AT kinoshitamanabu ni12theratiooft1weightedtot2weightedsignalintensityandidhmutationinglioma